LivaNova USA, Inc.
$26.3M 8,622 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
F. Hoffmann-La Roche AG
F. Hoffmann-La Roche AG reported $25,776,647.33 across General Payments, Research, and Ownership to 1,104 physicians and teaching hospitals across 6,185 transactions.
- $25.8M Top 10% payer
- All-tracks total
- 6,185 Top quartile volume
- Transactions
- 1,104 Above-median reach
- Recipients
- −$395.7K
- General Payments vs PY2023
F. Hoffmann-La Roche AG reported $25,776,647.33 across all CMS Open Payments tracks (General + Research + Ownership) to 1,104 physicians and teaching hospitals in Program Year 2024 - ranking #80 of 1,925 reporting manufacturers (0.2% of the all-tracks industry total); General Payments alone were $2,522,602.16, averaging $23.3K per recipient.
How F. Hoffmann-La Roche AG's $25.8M all-tracks total breaks down
F. Hoffmann-La Roche AG's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
D
59/100
Total payments
A
100/100
Transaction volume
D
55/100
Physician reach
F
18/100
Payment type diversity
D
63/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer f-hoffmann-la-roche-ag F. Hoffmann-La Roche AG
$25.8M · #80/1,925 · 0.2% industry · PY2024
- TOT $25.8M
- RANK #80
- SHARE 0.2%
- TXN 6,185
- RCP 1,104
- CAT 5
- GEN $2.5M
- ΔGEN −$395.7K
- TOP1 11.9%
- PY 2024
Volume peers
Nearest volume peer: LivaNova USA, Inc. ($26.3M)
F. Hoffmann-La Roche AG sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
F. Hoffmann-La Roche AG's CMS-reported General Payments decreased by $395.7K (−13.6%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: F. HOFFMANN-LA ROCHE AGPY2023: F. HOFFMANN-LA ROCHE AGPY2024: F. Hoffmann-La Roche AG. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $2,918,288.30
- PY2024
- $2,522,602.16
What the Data Shows for F. Hoffmann-La Roche AG
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For F. Hoffmann-La Roche AG, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
The 5-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $1.3M, accounting for 50.5% of this company's General Payments and 477 transactions.
General Payment Breakdown by Type
F. Hoffmann-La Roche AG made 5 types of general payments. "Consulting Fee" is the largest category at $1.3M, 50.5% of General Payments.
F. Hoffmann-La Roche AG reports 5 general-payment categories - the top three are Consulting Fee (50.5%), Travel and Lodging (34.2%), and Royalty or License (13.5%). The remaining 2 categories make up 1.8% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How F. Hoffmann-La Roche AG divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $1.3M | 477 | 50.5% |
| Travel and Lodging | $863.1K | 356 | 34.2% |
| Royalty or License | $340.0K | 4 | 13.5% |
| Food and Beverage | $36.6K | 256 | 1.5% |
| Compensation for Services Other Than Consulting | $9.8K | 11 | 0.4% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $497,722.06 (19.7%) of $2,522,602.16 in this company's General Payments records across 336 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for F. Hoffmann-La Roche AG
The five named recipients with the highest reported General Payments from this company
- 1
Ut Md Anderson Cancer Center
$300,000.00 across 1 reported transactions
- 2
Arshad Khanani
$80,674.94 across 25 reported transactions
- 3
Veeral Sheth
$42,865.01 across 20 reported transactions
- 4
Srinivas Sadda
$37,941.88 across 17 reported transactions
- 5
Richard Finn
$36,240.23 across 12 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
F. Hoffmann-La Roche AG ranks #80 of 1,925 by total payments (top 4% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,563 of 1,838 by HHI (bottom 15% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- SPR Therapeutics, Inc : $1.1M total payments, HHI 200
- Envista Holdings Corporation : $6.0M total payments, HHI 200
- Vericel Corporation : $1.3M total payments, HHI 200
- Straumann USA LLC : $7.6M total payments, HHI 200
- Eclipse Technology Solutions Inc. : $47.7K total payments, HHI 199
- Koya Medical, Inc. : $37.7K total payments, HHI 199
- F. Hoffmann-La Roche AG (this company) : $2.5M total payments, HHI 198
- Optinose US, Inc. : $1.3M total payments, HHI 196
- Tonix Medicines, Inc. : $63.3K total payments, HHI 196
- Patterson Companies, Inc. : $1.7M total payments, HHI 194
- Amneal Pharmaceuticals LLC : $1.9M total payments, HHI 194
- Rock Medical Orthopedics, Inc. : $23.5K total payments, HHI 194
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as F. Hoffmann-La Roche AG's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about F. Hoffmann-La Roche AG.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with F. Hoffmann-La Roche AG.
Showing 6 of 1,924 companies with CMS-reported payment data.
United Therapeutics Corporation
$26.6M 16,575 recipients
Compare payment profiles
Cardio Flow, Inc.
$26.8M 22 recipients
Compare payment profiles
Regeneron Healthcare Solutions, Inc.
$24.7M 169,362 recipients
Compare payment profiles
Henry Schein, Inc.
$27.4M 2,793 recipients
Compare payment profiles
Grace Medical, Inc.
$24.1M 51 recipients
Compare payment profiles
Put this to use
F. Hoffmann-La Roche AG ranks #80 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where F. Hoffmann-La Roche AG sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just F. Hoffmann-La Roche AG. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.